Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7b-5p AIFM1 0.13 0.6518 0.08 0.68492 miRNATAP -0.14 0.00399 NA
2 hsa-let-7i-5p AIFM1 -0.19 0.47734 0.08 0.68492 miRNATAP -0.21 0.00013 NA
3 hsa-miR-125a-5p AIFM1 -0.31 0.3708 0.08 0.68492 miRanda -0.11 0.00731 NA
4 hsa-miR-125b-5p AIFM1 0.4 0.2546 0.08 0.68492 miRNATAP -0.15 0.00022 NA
5 hsa-miR-145-5p AIFM1 -1.16 0.00337 0.08 0.68492 miRNATAP -0.08 0.02942 20332243 Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death
6 hsa-miR-155-5p AIFM1 -1.43 0.00781 0.08 0.68492 miRNAWalker2 validate -0.08 0.00165 NA
7 hsa-miR-199a-5p AIFM1 -0.21 0.63598 0.08 0.68492 miRanda -0.17 0 NA
8 hsa-miR-125b-5p AKT1 0.4 0.2546 0.04 0.7925 miRNAWalker2 validate; miRTarBase -0.11 0.0004 NA
9 hsa-miR-22-3p AKT2 0.02 0.94029 -0.15 0.46571 mirMAP -0.15 0.03865 NA
10 hsa-miR-326 AKT2 -0.75 0.13947 -0.15 0.46571 miRanda -0.06 0.03378 NA
11 hsa-miR-106b-5p AKT3 -0.81 0.00943 -0.53 0.25156 miRNATAP -0.54 0 NA
12 hsa-miR-17-3p AKT3 -0.07 0.78643 -0.53 0.25156 miRNATAP -0.52 9.0E-5 NA
13 hsa-miR-17-5p AKT3 -0.67 0.04231 -0.53 0.25156 TargetScan; miRNATAP -0.47 1.0E-5 NA
14 hsa-miR-181b-5p AKT3 0.25 0.56352 -0.53 0.25156 miRNATAP -0.16 0.03866 NA
15 hsa-miR-20a-5p AKT3 -0.39 0.26959 -0.53 0.25156 miRNATAP -0.47 0 NA
16 hsa-miR-29a-3p AKT3 -0.39 0.22665 -0.53 0.25156 miRNATAP -0.36 0.0009 NA
17 hsa-miR-29b-3p AKT3 -0.39 0.34358 -0.53 0.25156 miRNATAP -0.27 0.00119 26512921 MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3
18 hsa-miR-29c-3p AKT3 -0.13 0.74361 -0.53 0.25156 miRNAWalker2 validate; miRNATAP -0.17 0.03964 NA
19 hsa-miR-335-3p AKT3 -0.5 0.22325 -0.53 0.25156 mirMAP -0.3 0.00029 NA
20 hsa-miR-362-3p AKT3 -1.21 0.01257 -0.53 0.25156 miRanda -0.27 0.00013 NA
21 hsa-miR-362-5p AKT3 -0.73 0.11206 -0.53 0.25156 PITA; TargetScan; miRNATAP -0.3 5.0E-5 NA
22 hsa-miR-374b-5p AKT3 -0.94 0.0014 -0.53 0.25156 mirMAP -0.26 0.02459 NA
23 hsa-miR-502-3p AKT3 -0.73 0.03618 -0.53 0.25156 miRNATAP -0.35 0.00041 NA
24 hsa-miR-502-5p AKT3 -1.02 0.03949 -0.53 0.25156 PITA; miRNATAP -0.24 0.00053 NA
25 hsa-miR-505-3p AKT3 -1.26 0.00026 -0.53 0.25156 mirMAP -0.26 0.00822 22051041 We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR
26 hsa-miR-577 AKT3 0.81 0.31426 -0.53 0.25156 mirMAP -0.15 0.00024 NA
27 hsa-miR-93-5p AKT3 -0.47 0.13146 -0.53 0.25156 miRNATAP -0.56 0 NA
28 hsa-miR-18a-5p ATM -1.18 0.00436 -0.78 0.04275 miRNAWalker2 validate; miRTarBase; MirTarget -0.15 0.03076 23437304; 25963391; 23857602; 23229340 MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases
29 hsa-miR-203a-3p ATM 1.98 0.03266 -0.78 0.04275 MirTarget -0.08 0.00835 24145123; 27542403 miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression
30 hsa-miR-455-5p ATM -0.23 0.54044 -0.78 0.04275 miRanda -0.3 7.0E-5 NA
31 hsa-miR-127-3p BAD -0.03 0.94421 0.34 0.32274 miRanda; miRNATAP -0.18 0.00044 NA
32 hsa-miR-326 BAD -0.75 0.13947 0.34 0.32274 miRanda -0.25 0 NA
33 hsa-miR-30a-5p BAX -0.59 0.17531 -0.04 0.88535 miRNAWalker2 validate -0.09 0.04377 NA
34 hsa-miR-15b-3p BCL2 -0.79 0.05785 -1.63 0.00261 mirMAP -0.19 0.04998 25594541; 26915294; 26884837; 18449891 MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2
35 hsa-miR-16-2-3p BCL2 -1.03 0.00735 -1.63 0.00261 mirMAP -0.22 0.0345 NA
36 hsa-miR-17-5p BCL2 -0.67 0.04231 -1.63 0.00261 miRNAWalker2 validate; miRTarBase -0.29 0.02016 25435430 Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2
37 hsa-miR-182-5p BCL2 0.19 0.7303 -1.63 0.00261 miRNAWalker2 validate; miRTarBase; mirMAP -0.4 0 23936432; 26870290 Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR 182 and p21; Bcl2 and p21 were identified to be potential target genes of miR-182 in PC3 cells;The expression levels of B-cell lymphoma-2 Bcl-2 and microRNA-182 miR-182 were detected using western blot analysis and quantitative reverse transcription-polymerase chain reaction respectively; Mangiferin treatment was also able to significantly reduce Bcl-2 expression levels and enhance miR-182 expression in PC3 cells; Finally it was observed that mangiferin inhibited proliferation and induced apoptosis in PC3 human prostate cancer cells and this effect was correlated with downregulation of Bcl-2 and upregulation of miR-182
38 hsa-miR-192-5p BCL2 2.1 0.00233 -1.63 0.00261 miRNAWalker2 validate -0.31 0 26550150 MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192
39 hsa-miR-196b-5p BCL2 1.33 0.19807 -1.63 0.00261 miRNAWalker2 validate -0.13 0.00097 NA
40 hsa-miR-200a-5p BCL2 2.65 1.0E-5 -1.63 0.00261 mirMAP -0.37 0 NA
41 hsa-miR-200b-3p BCL2 1.84 0.00297 -1.63 0.00261 miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP -0.46 0 NA
42 hsa-miR-200b-5p BCL2 0.86 0.18327 -1.63 0.00261 mirMAP -0.46 0 NA
43 hsa-miR-200c-3p BCL2 1.56 0.01265 -1.63 0.00261 miRNAWalker2 validate; miRTarBase; mirMAP -0.4 0 NA
44 hsa-miR-20a-5p BCL2 -0.39 0.26959 -1.63 0.00261 miRNAWalker2 validate; miRTarBase -0.29 0.01076 NA
45 hsa-miR-215-5p BCL2 3.07 0.00158 -1.63 0.00261 miRNAWalker2 validate -0.11 0.00607 NA
46 hsa-miR-224-5p BCL2 -0.27 0.69436 -1.63 0.00261 mirMAP -0.19 0.00121 24796455 In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01
47 hsa-miR-29a-5p BCL2 -0.6 0.06643 -1.63 0.00261 mirMAP -0.25 0.04539 20041405 Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29
48 hsa-miR-29b-3p BCL2 -0.39 0.34358 -1.63 0.00261 miRNAWalker2 validate; miRTarBase -0.21 0.02912 20041405 Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29
49 hsa-miR-3065-5p BCL2 0.74 0.29684 -1.63 0.00261 mirMAP -0.12 0.0323 NA
50 hsa-miR-33a-5p BCL2 -0.99 0.06458 -1.63 0.00261 mirMAP -0.24 0.0011 NA
51 hsa-miR-33b-5p BCL2 0.62 0.3293 -1.63 0.00261 miRTarBase; mirMAP -0.19 0.00291 NA
52 hsa-miR-34a-5p BCL2 -0.24 0.41696 -1.63 0.00261 miRNAWalker2 validate; miRTarBase -0.4 0.0035 19714243; 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 25053345; 20433755; 21399894; 22964582; 23862748 Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression
53 hsa-miR-429 BCL2 1.86 0.00726 -1.63 0.00261 miRNAWalker2 validate; miRTarBase; PITA; mirMAP -0.4 0 23999873; 26513239; 26511969 MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation
54 hsa-miR-455-5p BCL2 -0.23 0.54044 -1.63 0.00261 mirMAP -0.37 0.0005 NA
55 hsa-miR-577 BCL2 0.81 0.31426 -1.63 0.00261 PITA -0.11 0.03266 NA
56 hsa-miR-582-5p BCL2 -0.24 0.6387 -1.63 0.00261 PITA -0.16 0.04038 NA
57 hsa-miR-96-5p BCL2 -0.14 0.83402 -1.63 0.00261 miRNAWalker2 validate; TargetScan -0.43 0 NA
58 hsa-let-7g-3p BCL2L1 -0.84 0.01923 0.86 0.00506 miRNATAP -0.18 0.0056 20347499 Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA
59 hsa-miR-140-5p BCL2L1 -1.2 4.0E-5 0.86 0.00506 PITA; miRanda; miRNATAP -0.31 6.0E-5 NA
60 hsa-miR-185-3p BCL2L1 -0.81 0.0588 0.86 0.00506 mirMAP; miRNATAP -0.13 0.0178 NA
61 hsa-miR-30b-3p BCL2L1 -0.57 0.2349 0.86 0.00506 MirTarget -0.14 0.00253 NA
62 hsa-miR-326 BCL2L1 -0.75 0.13947 0.86 0.00506 PITA; miRanda; mirMAP; miRNATAP -0.11 0.01797 NA
63 hsa-miR-330-5p BCL2L1 0.65 0.08635 0.86 0.00506 PITA; miRanda; miRNATAP -0.13 0.03818 NA
64 hsa-miR-342-3p BCL2L1 -1.51 0.00036 0.86 0.00506 PITA; miRanda; miRNATAP -0.19 0.00038 NA
65 hsa-miR-342-5p BCL2L1 -1.68 7.0E-5 0.86 0.00506 miRNATAP -0.17 0.00106 NA
66 hsa-miR-377-3p BCL2L1 -1.31 0.02275 0.86 0.00506 MirTarget -0.11 0.00391 NA
67 hsa-miR-421 BCL2L1 -0.18 0.69194 0.86 0.00506 miRanda -0.17 0.00128 NA
68 hsa-miR-484 BCL2L1 -1.18 5.0E-5 0.86 0.00506 miRNAWalker2 validate -0.19 0.01279 NA
69 hsa-miR-664a-5p BCL2L1 -0.92 0.03703 0.86 0.00506 mirMAP -0.19 0.00013 NA
70 hsa-miR-137 BID -0.08 0.93052 0.09 0.77131 miRanda -0.06 0.02093 NA
71 hsa-miR-370-3p BID -0.69 0.22721 0.09 0.77131 MirTarget -0.13 0.00091 NA
72 hsa-miR-543 BID -1.03 0.07135 0.09 0.77131 miRanda -0.1 0.00802 NA
73 hsa-miR-29b-3p BIRC2 -0.39 0.34358 -0.1 0.59262 MirTarget -0.11 0.00043 NA
74 hsa-miR-29c-3p BIRC2 -0.13 0.74361 -0.1 0.59262 MirTarget -0.09 0.00625 NA
75 hsa-miR-421 BIRC2 -0.18 0.69194 -0.1 0.59262 miRanda -0.06 0.03743 NA
76 hsa-miR-500a-5p BIRC2 -1.1 0.01791 -0.1 0.59262 MirTarget -0.08 0.00598 NA
77 hsa-miR-129-5p BIRC3 1.01 0.36712 -0.62 0.37166 miRanda -0.21 0 NA
78 hsa-miR-338-5p BIRC3 0.34 0.53294 -0.62 0.37166 mirMAP -0.21 0.02361 NA
79 hsa-miR-369-3p BIRC3 -0.83 0.17364 -0.62 0.37166 MirTarget; miRNATAP -0.41 0 NA
80 hsa-miR-375 BIRC3 2.46 0.01711 -0.62 0.37166 miRNAWalker2 validate -0.28 0 23726271 Taken together these data suggest that miR-375 sensitizes TNF-α-induced apoptosis and the reduction in the expression of the apoptosis inhibitory proteins cFLIP-L and cIAP2 plays an important role in this sensitization
81 hsa-miR-496 BIRC3 -0.26 0.66888 -0.62 0.37166 mirMAP -0.31 0.00016 NA
82 hsa-miR-577 BIRC3 0.81 0.31426 -0.62 0.37166 MirTarget -0.15 0.01912 NA
83 hsa-miR-664a-3p BIRC3 -0.55 0.06802 -0.62 0.37166 mirMAP -0.71 3.0E-5 NA
84 hsa-miR-98-5p BIRC3 -0.22 0.42277 -0.62 0.37166 miRNAWalker2 validate -1 0 NA
85 hsa-miR-140-5p CAPN1 -1.2 4.0E-5 0.32 0.26978 miRanda; miRNATAP -0.24 0.0007 NA
86 hsa-miR-491-5p CAPN1 -0.79 0.12393 0.32 0.26978 miRanda -0.13 0.00224 NA
87 hsa-miR-101-3p CAPN2 -0.27 0.36572 0.82 0.00458 miRNAWalker2 validate; MirTarget -0.31 2.0E-5 NA
88 hsa-miR-129-5p CAPN2 1.01 0.36712 0.82 0.00458 miRanda -0.08 6.0E-5 NA
89 hsa-miR-137 CAPN2 -0.08 0.93052 0.82 0.00458 MirTarget; PITA; miRanda -0.08 0.00069 NA
90 hsa-miR-1468-5p CAPN2 -0.37 0.52678 0.82 0.00458 MirTarget -0.18 0 NA
91 hsa-miR-421 CAPN2 -0.18 0.69194 0.82 0.00458 miRanda -0.17 0.00037 NA
92 hsa-miR-590-3p CAPN2 -0.92 0.03456 0.82 0.00458 miRanda -0.15 0.00183 NA
93 hsa-miR-590-5p CAPN2 -0.98 0.00534 0.82 0.00458 miRanda -0.19 0.00163 NA
94 hsa-miR-7-5p CAPN2 0.82 0.51059 0.82 0.00458 miRNAWalker2 validate -0.1 0 NA
95 hsa-miR-125a-5p CASP10 -0.31 0.3708 -0.18 0.62889 mirMAP -0.33 2.0E-5 NA
96 hsa-miR-129-2-3p CASP10 0.5 0.64185 -0.18 0.62889 mirMAP -0.13 0 NA
97 hsa-miR-129-5p CASP10 1.01 0.36712 -0.18 0.62889 mirMAP -0.13 0 NA
98 hsa-miR-144-5p CASP10 -2.21 0.00517 -0.18 0.62889 mirMAP -0.08 0.02097 NA
99 hsa-miR-148b-5p CASP10 -0.01 0.99005 -0.18 0.62889 mirMAP -0.2 3.0E-5 NA
100 hsa-miR-181c-5p CASP10 0.39 0.3054 -0.18 0.62889 mirMAP -0.19 0.00574 NA
101 hsa-miR-30b-3p CASP10 -0.57 0.2349 -0.18 0.62889 MirTarget -0.16 0.00438 NA
102 hsa-miR-338-3p CASP10 0.51 0.34448 -0.18 0.62889 miRanda -0.14 0.00315 NA
103 hsa-miR-338-5p CASP10 0.34 0.53294 -0.18 0.62889 mirMAP -0.12 0.0125 NA
104 hsa-miR-361-5p CASP10 -0.3 0.18864 -0.18 0.62889 miRanda -0.57 0 NA
105 hsa-miR-3613-3p CASP10 -0.97 0.05661 -0.18 0.62889 MirTarget -0.12 0.02434 NA
106 hsa-miR-421 CASP10 -0.18 0.69194 -0.18 0.62889 mirMAP -0.32 0 NA
107 hsa-miR-592 CASP10 1.03 0.22889 -0.18 0.62889 miRNATAP -0.12 0.00077 NA
108 hsa-miR-744-3p CASP10 -0.55 0.24228 -0.18 0.62889 mirMAP -0.34 0 NA
109 hsa-miR-129-5p CASP3 1.01 0.36712 -0.01 0.97941 mirMAP -0.06 2.0E-5 23744359 The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3
110 hsa-miR-137 CASP3 -0.08 0.93052 -0.01 0.97941 MirTarget; miRanda -0.06 0.00242 27429846 Oncogenic miR 137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma; Through computational prediction and microarray we identified caspase-3 CASP3 as a potential target of miR-137; Luciferase reporter and site-directed mutagenesis assays demonstrated that miR-137 downregulates CASP3 through binding to its 3'-UTR; Moreover the endogenous CASP3 can be modulated by overexpressing or silencing miR-137 in lung adenocarcinoma cell lines regardless of EGFR status; Suppression of CASP3 by miR-137 provides cancer cells with anti-apoptotic ability leading to cisplatin resistance; Immunohistochemistry results revealed an inverse correlation between miR-137 and CASP3 expressions in lung adenocarcinoma patients
111 hsa-miR-139-5p CASP3 -1.64 0.00654 -0.01 0.97941 miRanda -0.08 0.00324 NA
112 hsa-miR-30a-5p CASP3 -0.59 0.17531 -0.01 0.97941 miRNATAP -0.08 0.03017 NA
113 hsa-miR-30c-5p CASP3 -0.88 0.00777 -0.01 0.97941 miRNATAP -0.12 0.01479 NA
114 hsa-miR-98-5p CASP3 -0.22 0.42277 -0.01 0.97941 MirTarget -0.21 0.0004 NA
115 hsa-miR-125a-5p CASP6 -0.31 0.3708 0.22 0.45531 miRanda -0.34 0 NA
116 hsa-miR-129-5p CASP6 1.01 0.36712 0.22 0.45531 MirTarget; miRanda -0.11 0 NA
117 hsa-miR-369-3p CASP6 -0.83 0.17364 0.22 0.45531 MirTarget -0.15 2.0E-5 NA
118 hsa-miR-129-5p CASP7 1.01 0.36712 0.21 0.50664 miRanda -0.07 0.00076 NA
119 hsa-miR-132-3p CASP7 -0.19 0.63856 0.21 0.50664 miRNAWalker2 validate; MirTarget -0.29 0 NA
120 hsa-miR-137 CASP7 -0.08 0.93052 0.21 0.50664 miRanda -0.12 1.0E-5 NA
121 hsa-miR-212-3p CASP7 -0.37 0.45016 0.21 0.50664 MirTarget -0.18 8.0E-5 NA
122 hsa-miR-3065-3p CASP7 0.92 0.14952 0.21 0.50664 MirTarget -0.15 2.0E-5 NA
123 hsa-miR-361-5p CASP7 -0.3 0.18864 0.21 0.50664 PITA; miRanda -0.37 0.00041 NA
124 hsa-miR-543 CASP7 -1.03 0.07135 0.21 0.50664 miRanda -0.16 6.0E-5 NA
125 hsa-miR-664a-3p CASP7 -0.55 0.06802 0.21 0.50664 MirTarget -0.19 0.01551 NA
126 hsa-miR-107 CASP8 0.04 0.89912 -0.22 0.5858 miRanda -0.22 0.03943 NA
127 hsa-miR-129-5p CASP8 1.01 0.36712 -0.22 0.5858 miRanda -0.17 0 NA
128 hsa-miR-137 CASP8 -0.08 0.93052 -0.22 0.5858 miRanda -0.08 0.016 NA
129 hsa-miR-296-3p CASP8 -0.4 0.5034 -0.22 0.5858 miRanda -0.15 0.00785 NA
130 hsa-miR-3607-3p CASP8 -0.1 0.81827 -0.22 0.5858 mirMAP -0.16 0.02174 NA
131 hsa-miR-3613-3p CASP8 -0.97 0.05661 -0.22 0.5858 mirMAP -0.12 0.04936 NA
132 hsa-miR-376a-3p CASP8 -0.6 0.34279 -0.22 0.5858 TargetScan -0.23 0 NA
133 hsa-miR-421 CASP8 -0.18 0.69194 -0.22 0.5858 miRanda -0.31 0 NA
134 hsa-miR-543 CASP8 -1.03 0.07135 -0.22 0.5858 miRanda -0.23 1.0E-5 NA
135 hsa-miR-125b-2-3p CASP9 0.59 0.24105 -0.26 0.21002 mirMAP -0.08 0.01092 NA
136 hsa-miR-103a-2-5p CFLAR -2.06 0.00116 -0.19 0.52443 mirMAP -0.08 0.01923 NA
137 hsa-miR-125a-5p CFLAR -0.31 0.3708 -0.19 0.52443 miRanda -0.23 0.00048 NA
138 hsa-miR-301a-3p CFLAR -0.76 0.09613 -0.19 0.52443 mirMAP -0.2 2.0E-5 NA
139 hsa-miR-30b-3p CFLAR -0.57 0.2349 -0.19 0.52443 mirMAP -0.12 0.00905 NA
140 hsa-miR-338-3p CFLAR 0.51 0.34448 -0.19 0.52443 miRanda; mirMAP -0.14 0.00067 NA
141 hsa-miR-3613-3p CFLAR -0.97 0.05661 -0.19 0.52443 mirMAP -0.09 0.0449 NA
142 hsa-miR-377-3p CFLAR -1.31 0.02275 -0.19 0.52443 mirMAP -0.17 0 NA
143 hsa-miR-421 CFLAR -0.18 0.69194 -0.19 0.52443 miRanda -0.13 0.00909 NA
144 hsa-miR-454-3p CFLAR -1.27 0.00176 -0.19 0.52443 mirMAP -0.11 0.04499 NA
145 hsa-miR-455-5p CFLAR -0.23 0.54044 -0.19 0.52443 miRanda -0.19 0.00111 NA
146 hsa-miR-543 CFLAR -1.03 0.07135 -0.19 0.52443 miRanda -0.15 6.0E-5 NA
147 hsa-miR-550a-5p CFLAR 0.44 0.37018 -0.19 0.52443 mirMAP -0.11 0.01176 NA
148 hsa-miR-660-5p CFLAR -0.2 0.55612 -0.19 0.52443 mirMAP -0.16 0.01845 NA
149 hsa-miR-7-5p CFLAR 0.82 0.51059 -0.19 0.52443 miRNAWalker2 validate -0.11 0 NA
150 hsa-miR-130a-5p CHUK -1.25 0.01164 0.14 0.4695 MirTarget; miRNATAP -0.08 0.00626 NA
NumGOOverlapSizeP ValueAdj. P Value
1 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 24 99 3.326e-38 1.548e-34
2 POSITIVE REGULATION OF RESPONSE TO STIMULUS 53 1929 1.52e-37 3.535e-34
3 INTRACELLULAR SIGNAL TRANSDUCTION 49 1572 1.877e-36 2.319e-33
4 REGULATION OF CELL DEATH 48 1472 1.994e-36 2.319e-33
5 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 18 39 1.055e-34 9.815e-32
6 APOPTOTIC SIGNALING PATHWAY 29 289 1.825e-34 1.415e-31
7 CELL DEATH 41 1001 5.008e-34 3.329e-31
8 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 48 1848 7.665e-32 4.458e-29
9 POSITIVE REGULATION OF CELL COMMUNICATION 45 1532 1.175e-31 6.076e-29
10 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 25 213 2.54e-31 1.182e-28
11 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 44 1492 7.167e-31 3.032e-28
12 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 37 876 9.652e-31 3.742e-28
13 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 20 95 1.946e-30 6.964e-28
14 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 45 1656 3.387e-30 1.126e-27
15 RESPONSE TO OXYGEN CONTAINING COMPOUND 42 1381 9.993e-30 2.949e-27
16 POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 23 179 1.014e-29 2.949e-27
17 NEGATIVE REGULATION OF CELL DEATH 36 872 1.823e-29 4.991e-27
18 ZYMOGEN ACTIVATION 20 112 7.098e-29 1.835e-26
19 POSITIVE REGULATION OF MOLECULAR FUNCTION 45 1791 9.785e-29 2.396e-26
20 RESPONSE TO CYTOKINE 33 714 2.4e-28 5.583e-26
21 IMMUNE SYSTEM PROCESS 46 1984 5.176e-28 1.147e-25
22 REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 23 233 5.438e-27 1.15e-24
23 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 20 154 6.218e-26 1.228e-23
24 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 13 6.335e-26 1.228e-23
25 POSITIVE REGULATION OF CELL DEATH 29 605 3.946e-25 7.344e-23
26 REGULATION OF PEPTIDASE ACTIVITY 25 392 1.376e-24 2.463e-22
27 POSITIVE REGULATION OF CATALYTIC ACTIVITY 39 1518 1.541e-24 2.655e-22
28 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 17 98 2.303e-24 3.827e-22
29 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 19 153 2.918e-24 4.681e-22
30 PROTEIN MATURATION 22 265 4.001e-24 6.206e-22
31 POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 17 9.936e-24 1.491e-21
32 REGULATION OF IMMUNE SYSTEM PROCESS 37 1403 1.753e-23 2.549e-21
33 REGULATION OF APOPTOTIC SIGNALING PATHWAY 23 363 1.594e-22 2.248e-20
34 CELLULAR RESPONSE TO CYTOKINE STIMULUS 27 606 1.747e-22 2.391e-20
35 ACTIVATION OF IMMUNE RESPONSE 24 427 2.783e-22 3.699e-20
36 REGULATION OF IMMUNE RESPONSE 30 858 4.458e-22 5.761e-20
37 POSITIVE REGULATION OF IMMUNE RESPONSE 26 563 5.152e-22 6.479e-20
38 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 22 5.582e-22 6.835e-20
39 REGULATION OF PROTEOLYSIS 28 711 6.634e-22 7.915e-20
40 CYTOKINE MEDIATED SIGNALING PATHWAY 24 452 1.064e-21 1.238e-19
41 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 18 171 1.149e-21 1.304e-19
42 RESPONSE TO NITROGEN COMPOUND 29 859 7.096e-21 7.862e-19
43 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 29 867 9.159e-21 9.911e-19
44 RESPONSE TO TUMOR NECROSIS FACTOR 19 233 1.054e-20 1.114e-18
45 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 18 200 2.048e-20 2.118e-18
46 REGULATION OF TRANSFERASE ACTIVITY 29 946 9.989e-20 9.683e-18
47 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 31 1135 9.98e-20 9.683e-18
48 POSITIVE REGULATION OF PROTEOLYSIS 21 363 9.678e-20 9.683e-18
49 REGULATION OF KINASE ACTIVITY 27 776 1.06e-19 1.007e-17
50 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 11 34 2.187e-19 2.035e-17
51 REGULATION OF PHOSPHORUS METABOLIC PROCESS 35 1618 2.936e-19 2.679e-17
52 I KAPPAB KINASE NF KAPPAB SIGNALING 13 70 3.224e-19 2.885e-17
53 ACTIVATION OF INNATE IMMUNE RESPONSE 17 204 9.825e-19 8.626e-17
54 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 29 1036 1.179e-18 9.973e-17
55 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 29 1036 1.179e-18 9.973e-17
56 REGULATION OF RESPONSE TO STRESS 33 1468 1.554e-18 1.291e-16
57 POSITIVE REGULATION OF KINASE ACTIVITY 22 482 1.808e-18 1.476e-16
58 POSITIVE REGULATION OF DEFENSE RESPONSE 20 364 2.275e-18 1.825e-16
59 PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 14 109 2.992e-18 2.36e-16
60 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 26 799 3.136e-18 2.432e-16
61 REGULATION OF RESPONSE TO CYTOKINE STIMULUS 15 144 4.363e-18 3.328e-16
62 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 19 321 4.54e-18 3.407e-16
63 TOLL LIKE RECEPTOR SIGNALING PATHWAY 13 85 4.809e-18 3.552e-16
64 TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 14 118 9.494e-18 6.902e-16
65 RESPONSE TO ABIOTIC STIMULUS 28 1024 1.036e-17 7.416e-16
66 REGULATION OF PROTEIN MODIFICATION PROCESS 34 1710 1.646e-17 1.161e-15
67 POSITIVE REGULATION OF INNATE IMMUNE RESPONSE 17 246 2.382e-17 1.654e-15
68 REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 11 50 2.726e-17 1.865e-15
69 RESPONSE TO BIOTIC STIMULUS 26 886 3.893e-17 2.625e-15
70 PROTEOLYSIS 29 1208 7.231e-17 4.806e-15
71 CELLULAR RESPONSE TO ABIOTIC STIMULUS 17 263 7.352e-17 4.818e-15
72 CELLULAR RESPONSE TO NITROGEN COMPOUND 21 505 8.143e-17 5.262e-15
73 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 11 55 8.606e-17 5.485e-15
74 RESPONSE TO ENDOGENOUS STIMULUS 31 1450 1.078e-16 6.778e-15
75 PHOSPHORYLATION 29 1228 1.118e-16 6.935e-15
76 ACTIVATION OF PROTEIN KINASE ACTIVITY 17 279 1.981e-16 1.213e-14
77 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 22 616 3.155e-16 1.907e-14
78 INTRINSIC APOPTOTIC SIGNALING PATHWAY 14 152 3.595e-16 2.145e-14
79 REGULATION OF INNATE IMMUNE RESPONSE 18 357 6.469e-16 3.81e-14
80 REGULATION OF HYDROLASE ACTIVITY 29 1327 8.637e-16 5.023e-14
81 REGULATION OF NEURON DEATH 16 252 8.78e-16 5.044e-14
82 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 34 1977 1.354e-15 7.683e-14
83 POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY 13 132 1.834e-15 1.028e-13
84 PROTEIN PHOSPHORYLATION 25 944 1.988e-15 1.101e-13
85 IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 17 323 2.27e-15 1.242e-13
86 INFLAMMATORY RESPONSE 19 454 2.717e-15 1.47e-13
87 SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 9 33 2.821e-15 1.492e-13
88 EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 9 33 2.821e-15 1.492e-13
89 RESPONSE TO BACTERIUM 20 528 2.974e-15 1.555e-13
90 POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 15 228 4.52e-15 2.337e-13
91 NEURON APOPTOTIC PROCESS 9 35 5.134e-15 2.597e-13
92 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 19 470 5.094e-15 2.597e-13
93 RESPONSE TO LIPID 24 888 5.376e-15 2.69e-13
94 CELLULAR RESPONSE TO MECHANICAL STIMULUS 11 80 7.009e-15 3.47e-13
95 RESPONSE TO EXTERNAL STIMULUS 32 1821 7.661e-15 3.746e-13
96 CELLULAR RESPONSE TO STRESS 30 1565 7.728e-15 3.746e-13
97 POSITIVE REGULATION OF HYDROLASE ACTIVITY 24 905 8.17e-15 3.919e-13
98 REGULATION OF CELL PROLIFERATION 29 1496 1.952e-14 9.268e-13
99 REGULATION OF DEFENSE RESPONSE 22 759 2.321e-14 1.091e-12
100 REGULATION OF NECROTIC CELL DEATH 8 26 3.522e-14 1.639e-12
101 RESPONSE TO HORMONE 23 893 6.313e-14 2.908e-12
102 NECROTIC CELL DEATH 8 28 6.966e-14 3.178e-12
103 NEURON DEATH 9 47 9.566e-14 4.321e-12
104 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 10 71 9.861e-14 4.412e-12
105 MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 8 30 1.304e-13 5.779e-12
106 FC EPSILON RECEPTOR SIGNALING PATHWAY 12 142 1.542e-13 6.769e-12
107 IMMUNE RESPONSE 24 1100 5.716e-13 2.486e-11
108 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 8 36 6.625e-13 2.854e-11
109 CELLULAR RESPONSE TO EXTERNAL STIMULUS 14 264 7.775e-13 3.319e-11
110 POSITIVE REGULATION OF NEURON DEATH 9 67 2.831e-12 1.197e-10
111 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 8 43 3.11e-12 1.304e-10
112 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 15 360 3.517e-12 1.461e-10
113 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 15 365 4.282e-12 1.748e-10
114 REGULATION OF MEMBRANE PERMEABILITY 9 70 4.268e-12 1.748e-10
115 HOMEOSTATIC PROCESS 25 1337 4.95e-12 2.003e-10
116 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 15 370 5.2e-12 2.086e-10
117 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 8 46 5.547e-12 2.206e-10
118 ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY 12 195 6.797e-12 2.68e-10
119 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 25 1360 7.184e-12 2.809e-10
120 NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY 7 28 7.896e-12 3.062e-10
121 RESPONSE TO ORGANIC CYCLIC COMPOUND 21 917 9.27e-12 3.565e-10
122 PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS 8 49 9.503e-12 3.624e-10
123 T CELL APOPTOTIC PROCESS 6 15 1.017e-11 3.846e-10
124 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 7 29 1.038e-11 3.863e-10
125 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 7 29 1.038e-11 3.863e-10
126 FC RECEPTOR SIGNALING PATHWAY 12 206 1.296e-11 4.787e-10
127 RESPONSE TO MECHANICAL STIMULUS 12 210 1.624e-11 5.952e-10
128 NIK NF KAPPAB SIGNALING 9 83 2.076e-11 7.548e-10
129 CELLULAR RESPONSE TO PEPTIDE 13 274 2.24e-11 8.08e-10
130 NEGATIVE REGULATION OF CELL COMMUNICATION 23 1192 2.419e-11 8.658e-10
131 EXECUTION PHASE OF APOPTOSIS 8 55 2.521e-11 8.954e-10
132 CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 7 33 2.808e-11 9.897e-10
133 T CELL HOMEOSTASIS 7 34 3.525e-11 1.233e-09
134 POSITIVE REGULATION OF GENE EXPRESSION 27 1733 3.611e-11 1.254e-09
135 LYMPHOCYTE APOPTOTIC PROCESS 6 18 3.738e-11 1.289e-09
136 DEFENSE RESPONSE 23 1231 4.618e-11 1.58e-09
137 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 16 514 4.895e-11 1.662e-09
138 MITOCHONDRIAL MEMBRANE ORGANIZATION 9 92 5.345e-11 1.802e-09
139 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 21 1008 5.43e-11 1.818e-09
140 NECROPTOTIC PROCESS 6 21 1.083e-10 3.6e-09
141 REGULATION OF CATABOLIC PROCESS 18 731 1.175e-10 3.873e-09
142 REGULATION OF NEURON APOPTOTIC PROCESS 11 192 1.182e-10 3.873e-09
143 CELLULAR RESPONSE TO HORMONE STIMULUS 16 552 1.401e-10 4.527e-09
144 REGULATION OF CELLULAR PROTEIN LOCALIZATION 16 552 1.401e-10 4.527e-09
145 STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 9 103 1.495e-10 4.797e-09
146 T CELL RECEPTOR SIGNALING PATHWAY 10 146 1.518e-10 4.838e-09
147 RESPONSE TO WOUNDING 16 563 1.871e-10 5.923e-09
148 LEUKOCYTE APOPTOTIC PROCESS 6 23 2.003e-10 6.299e-09
149 RESPONSE TO PEPTIDE 14 404 2.283e-10 7.13e-09
150 REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 7 44 2.438e-10 7.564e-09
151 CHEMICAL HOMEOSTASIS 19 874 2.683e-10 8.267e-09
152 REGULATION OF NECROPTOTIC PROCESS 5 11 2.744e-10 8.401e-09
153 RESPONSE TO AMINO ACID 9 112 3.188e-10 9.694e-09
154 PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 6 25 3.494e-10 1.056e-08
155 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 7 47 3.967e-10 1.191e-08
156 RESPONSE TO INTERLEUKIN 1 9 115 4.044e-10 1.206e-08
157 REGULATION OF MITOCHONDRION ORGANIZATION 11 218 4.591e-10 1.361e-08
158 RESPONSE TO OXIDATIVE STRESS 13 352 4.962e-10 1.461e-08
159 PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS 9 120 5.926e-10 1.734e-08
160 LYMPHOCYTE HOMEOSTASIS 7 50 6.245e-10 1.816e-08
161 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 12 289 6.521e-10 1.885e-08
162 INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY 5 13 7.601e-10 2.183e-08
163 INOSITOL LIPID MEDIATED SIGNALING 9 124 7.947e-10 2.269e-08
164 REGULATION OF ORGANELLE ORGANIZATION 21 1178 9.407e-10 2.669e-08
165 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 7 53 9.552e-10 2.694e-08
166 CELLULAR RESPONSE TO INTERLEUKIN 1 8 88 1.208e-09 3.385e-08
167 NEGATIVE REGULATION OF MOLECULAR FUNCTION 20 1079 1.334e-09 3.717e-08
168 WOUND HEALING 14 470 1.626e-09 4.502e-08
169 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 6 32 1.752e-09 4.795e-08
170 NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 6 32 1.752e-09 4.795e-08
171 REGULATION OF MAP KINASE ACTIVITY 12 319 2e-09 5.441e-08
172 CELL ACTIVATION 15 568 2.041e-09 5.522e-08
173 RESPONSE TO INORGANIC SUBSTANCE 14 479 2.074e-09 5.578e-08
174 LEUKOCYTE HOMEOSTASIS 7 60 2.345e-09 6.27e-08
175 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 25 1805 2.91e-09 7.736e-08
176 ACTIVATION OF PROTEIN KINASE A ACTIVITY 5 17 3.613e-09 9.552e-08
177 PEPTIDYL SERINE MODIFICATION 9 148 3.824e-09 1.005e-07
178 POSITIVE REGULATION OF TRANSPORT 18 936 6e-09 1.568e-07
179 REGULATION OF INTRACELLULAR TRANSPORT 15 621 6.806e-09 1.769e-07
180 REGULATION OF PROTEIN LOCALIZATION 18 950 7.56e-09 1.954e-07
181 LEUKOCYTE DIFFERENTIATION 11 292 9.843e-09 2.518e-07
182 REGULATION OF NIK NF KAPPAB SIGNALING 6 42 9.85e-09 2.518e-07
183 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 9 167 1.104e-08 2.806e-07
184 CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS 6 43 1.141e-08 2.886e-07
185 CELLULAR GLUCOSE HOMEOSTASIS 7 75 1.153e-08 2.9e-07
186 GLUCOSE HOMEOSTASIS 9 170 1.289e-08 3.208e-07
187 CARBOHYDRATE HOMEOSTASIS 9 170 1.289e-08 3.208e-07
188 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 13 465 1.414e-08 3.499e-07
189 RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 5 22 1.516e-08 3.731e-07
190 REGULATION OF MAPK CASCADE 15 660 1.535e-08 3.739e-07
191 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 121 1.534e-08 3.739e-07
192 POSITIVE REGULATION OF MAPK CASCADE 13 470 1.604e-08 3.888e-07
193 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 18 1004 1.777e-08 4.285e-07
194 MITOCHONDRIAL TRANSPORT 9 177 1.832e-08 4.393e-07
195 RESPONSE TO OXYGEN LEVELS 11 311 1.885e-08 4.475e-07
196 HEMOSTASIS 11 311 1.885e-08 4.475e-07
197 RESPONSE TO TOXIC SUBSTANCE 10 241 1.959e-08 4.626e-07
198 RESPONSE TO UV 8 126 2.11e-08 4.959e-07
199 RESPONSE TO ACID CHEMICAL 11 319 2.446e-08 5.663e-07
200 IMMUNE SYSTEM DEVELOPMENT 14 582 2.445e-08 5.663e-07
201 REGULATION OF EXECUTION PHASE OF APOPTOSIS 5 24 2.432e-08 5.663e-07
202 RESPONSE TO VIRUS 10 247 2.472e-08 5.695e-07
203 MITOCHONDRION ORGANIZATION 14 594 3.154e-08 7.228e-07
204 POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 6 51 3.294e-08 7.476e-07
205 RESPONSE TO NICOTINE 6 51 3.294e-08 7.476e-07
206 LEUKOCYTE CELL CELL ADHESION 10 255 3.341e-08 7.547e-07
207 NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 7 88 3.55e-08 7.941e-07
208 RESPONSE TO REACTIVE OXYGEN SPECIES 9 191 3.542e-08 7.941e-07
209 POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 6 52 3.713e-08 8.266e-07
210 PHOSPHATIDYLINOSITOL METABOLIC PROCESS 9 193 3.875e-08 8.586e-07
211 RESPONSE TO ALKALOID 8 137 4.066e-08 8.966e-07
212 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 16 829 4.645e-08 1.02e-06
213 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 15 720 4.84e-08 1.057e-06
214 LYMPHOCYTE ACTIVATION 11 342 4.979e-08 1.083e-06
215 POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 5 28 5.559e-08 1.203e-06
216 POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 4 11 5.587e-08 1.203e-06
217 RESPONSE TO DRUG 12 431 5.651e-08 1.212e-06
218 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 18 1087 5.97e-08 1.272e-06
219 NEGATIVE REGULATION OF CATABOLIC PROCESS 9 203 5.985e-08 1.272e-06
220 PROTEIN OLIGOMERIZATION 12 434 6.095e-08 1.289e-06
221 REGULATION OF CELL ADHESION 14 629 6.414e-08 1.351e-06
222 APOPTOTIC MITOCHONDRIAL CHANGES 6 57 6.522e-08 1.367e-06
223 POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING 5 29 6.698e-08 1.398e-06
224 POSITIVE REGULATION OF MAP KINASE ACTIVITY 9 207 7.075e-08 1.47e-06
225 REGULATION OF TRANSPORT 23 1804 7.234e-08 1.496e-06
226 LIPID PHOSPHORYLATION 7 99 8.06e-08 1.659e-06
227 GLYCEROLIPID BIOSYNTHETIC PROCESS 9 211 8.335e-08 1.705e-06
228 POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 12 8.356e-08 1.705e-06
229 REGULATION OF LIPID METABOLIC PROCESS 10 282 8.594e-08 1.746e-06
230 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 22 1672 8.782e-08 1.777e-06
231 REGULATION OF GLUCOSE IMPORT 6 60 8.919e-08 1.797e-06
232 RENAL SYSTEM PROCESS 7 102 9.911e-08 1.988e-06
233 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 20 1395 1.004e-07 2.004e-06
234 PROTEIN COMPLEX BIOGENESIS 18 1132 1.1e-07 2.177e-06
235 PROTEIN COMPLEX ASSEMBLY 18 1132 1.1e-07 2.177e-06
236 MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 5 32 1.126e-07 2.211e-06
237 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 5 32 1.126e-07 2.211e-06
238 HEPATOCYTE APOPTOTIC PROCESS 4 13 1.204e-07 2.343e-06
239 RESPONSE TO COBALT ION 4 13 1.204e-07 2.343e-06
240 REGULATION OF INFLAMMATORY RESPONSE 10 294 1.267e-07 2.456e-06
241 REGULATION OF CELLULAR LOCALIZATION 19 1277 1.277e-07 2.466e-06
242 INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 7 106 1.293e-07 2.485e-06
243 REGULATION OF CYTOKINE PRODUCTION 13 563 1.319e-07 2.526e-06
244 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 18 1152 1.429e-07 2.725e-06
245 RENAL WATER HOMEOSTASIS 5 34 1.547e-07 2.926e-06
246 CELLULAR RESPONSE TO ALKALOID 5 34 1.547e-07 2.926e-06
247 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 13 573 1.615e-07 3.043e-06
248 TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY 4 14 1.68e-07 3.153e-06
249 RESPONSE TO CARBOHYDRATE 8 168 1.973e-07 3.687e-06
250 REGULATION OF CELL ACTIVATION 12 484 1.982e-07 3.689e-06
251 PROTEIN HETEROOLIGOMERIZATION 7 113 2.007e-07 3.72e-06
252 PHOSPHOLIPID BIOSYNTHETIC PROCESS 9 235 2.085e-07 3.85e-06
253 NEGATIVE REGULATION OF NEURON DEATH 8 171 2.26e-07 4.157e-06
254 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 11 404 2.663e-07 4.878e-06
255 CELLULAR RESPONSE TO GLUCAGON STIMULUS 5 38 2.759e-07 5.034e-06
256 RESPONSE TO CORTICOSTEROID 8 176 2.818e-07 5.122e-06
257 REGULATION OF CELL DIFFERENTIATION 20 1492 2.98e-07 5.395e-06
258 CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS 6 74 3.168e-07 5.714e-06
259 RESPONSE TO RADIATION 11 413 3.315e-07 5.956e-06
260 LEUKOCYTE ACTIVATION 11 414 3.396e-07 6.058e-06
261 REGULATION OF AUTOPHAGY 9 249 3.398e-07 6.058e-06
262 RESPONSE TO KETONE 8 182 3.64e-07 6.465e-06
263 REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 4 17 3.962e-07 6.957e-06
264 ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY 4 17 3.962e-07 6.957e-06
265 REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 17 3.962e-07 6.957e-06
266 RESPONSE TO METAL ION 10 333 4e-07 6.996e-06
267 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 9 258 4.579e-07 7.98e-06
268 POSITIVE REGULATION OF GLUCOSE TRANSPORT 5 42 4.622e-07 8.025e-06
269 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 7 128 4.7e-07 8.13e-06
270 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 129 4.955e-07 8.54e-06
271 INSULIN RECEPTOR SIGNALING PATHWAY 6 80 5.05e-07 8.671e-06
272 AGING 9 264 5.551e-07 9.496e-06
273 JNK CASCADE 6 82 5.851e-07 9.972e-06
274 MULTICELLULAR ORGANISMAL HOMEOSTASIS 9 272 7.123e-07 1.21e-05
275 RESPONSE TO ALCOHOL 10 362 8.561e-07 1.448e-05
276 RESPONSE TO GLUCAGON 5 48 9.144e-07 1.542e-05
277 SINGLE ORGANISM CELL ADHESION 11 459 9.387e-07 1.577e-05
278 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 9 282 9.618e-07 1.61e-05
279 CELL PROLIFERATION 13 672 9.831e-07 1.64e-05
280 CELLULAR RESPONSE TO OXYGEN LEVELS 7 143 9.945e-07 1.653e-05
281 LYMPHOCYTE DIFFERENTIATION 8 209 1.038e-06 1.718e-05
282 POSITIVE REGULATION OF CYTOKINE PRODUCTION 10 370 1.043e-06 1.722e-05
283 CELLULAR HOMEOSTASIS 13 676 1.05e-06 1.727e-05
284 REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 7 145 1.092e-06 1.789e-05
285 RESPONSE TO GAMMA RADIATION 5 50 1.125e-06 1.83e-05
286 CELLULAR CHEMICAL HOMEOSTASIS 12 570 1.122e-06 1.83e-05
287 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 21 1784 1.189e-06 1.928e-05
288 POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION 4 22 1.201e-06 1.933e-05
289 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 13 684 1.198e-06 1.933e-05
290 REGULATION OF CELL CELL ADHESION 10 380 1.327e-06 2.129e-05
291 REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 6 95 1.398e-06 2.236e-05
292 POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 4 23 1.45e-06 2.31e-05
293 GLYCEROPHOSPHOLIPID METABOLIC PROCESS 9 297 1.477e-06 2.345e-05
294 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 7 152 1.498e-06 2.371e-05
295 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 220 1.525e-06 2.405e-05
296 IMMUNE EFFECTOR PROCESS 11 486 1.638e-06 2.574e-05
297 REGULATION OF CELL CYCLE 15 949 1.643e-06 2.574e-05
298 REGULATION OF GLUCOSE TRANSPORT 6 100 1.89e-06 2.951e-05
299 REGULATION OF HOMOTYPIC CELL CELL ADHESION 9 307 1.94e-06 3.019e-05
300 PROTEIN COMPLEX SUBUNIT ORGANIZATION 19 1527 1.952e-06 3.028e-05
301 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 10 397 1.966e-06 3.039e-05
302 RESPONSE TO STEROID HORMONE 11 497 2.034e-06 3.133e-05
303 EPITHELIAL CELL APOPTOTIC PROCESS 4 25 2.059e-06 3.162e-05
304 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 8 233 2.34e-06 3.582e-05
305 MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS 5 58 2.378e-06 3.616e-05
306 POSITIVE REGULATION OF PROTEIN IMPORT 6 104 2.378e-06 3.616e-05
307 CELLULAR RESPONSE TO BIOTIC STIMULUS 7 163 2.389e-06 3.62e-05
308 MACROMOLECULAR COMPLEX ASSEMBLY 18 1398 2.399e-06 3.624e-05
309 REGULATION OF BODY FLUID LEVELS 11 506 2.418e-06 3.641e-05
310 REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 5 59 2.59e-06 3.888e-05
311 REGULATION OF RESPONSE TO WOUNDING 10 413 2.797e-06 4.185e-05
312 INTRACELLULAR RECEPTOR SIGNALING PATHWAY 7 168 2.92e-06 4.354e-05
313 RESPONSE TO HYDROGEN PEROXIDE 6 109 3.128e-06 4.649e-05
314 CELL DEVELOPMENT 18 1426 3.175e-06 4.705e-05
315 POSITIVE REGULATION OF CELL CELL ADHESION 8 243 3.196e-06 4.721e-05
316 HOMEOSTASIS OF NUMBER OF CELLS 7 175 3.826e-06 5.633e-05
317 MEMBRANE ORGANIZATION 14 899 4.578e-06 6.719e-05
318 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 6 118 4.957e-06 7.254e-05
319 LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY 4 31 5.037e-06 7.346e-05
320 LEUKOCYTE MIGRATION 8 259 5.116e-06 7.439e-05
321 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 6 122 6.011e-06 8.713e-05
322 WATER HOMEOSTASIS 5 70 6.068e-06 8.768e-05
323 MYELOID CELL DIFFERENTIATION 7 189 6.35e-06 9.148e-05
324 GLYCEROLIPID METABOLIC PROCESS 9 356 6.472e-06 9.295e-05
325 CELLULAR RESPONSE TO LIPID 10 457 6.836e-06 9.788e-05
326 PROTEIN AUTOPHOSPHORYLATION 7 192 7.041e-06 0.0001005
327 PROTEIN KINASE B SIGNALING 4 34 7.361e-06 0.0001047
328 PHOSPHOLIPID METABOLIC PROCESS 9 364 7.739e-06 0.0001098
329 NEGATIVE REGULATION OF NECROTIC CELL DEATH 3 11 7.854e-06 0.0001111
330 POSITIVE REGULATION OF CELL PROLIFERATION 13 814 8.034e-06 0.0001133
331 REGULATION OF CELLULAR RESPONSE TO STRESS 12 691 8.108e-06 0.000114
332 REGULATION OF PROTEIN OLIGOMERIZATION 4 35 8.288e-06 0.0001162
333 RESPONSE TO LIGHT STIMULUS 8 280 9.047e-06 0.0001264
334 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 9 372 9.212e-06 0.0001283
335 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 14 957 9.347e-06 0.0001298
336 B CELL ACTIVATION 6 132 9.457e-06 0.000131
337 REGULATION OF ENDOTHELIAL CELL DEVELOPMENT 3 12 1.044e-05 0.0001438
338 REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER 3 12 1.044e-05 0.0001438
339 REGULATION OF CYTOPLASMIC TRANSPORT 10 481 1.068e-05 0.0001466
340 RESPONSE TO INSULIN 7 205 1.08e-05 0.0001478
341 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 9 381 1.115e-05 0.0001521
342 CELLULAR RESPONSE TO RADIATION 6 137 1.17e-05 0.0001587
343 ACTIVATION OF MAPK ACTIVITY 6 137 1.17e-05 0.0001587
344 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 6 138 1.22e-05 0.000165
345 LIPID MODIFICATION 7 210 1.263e-05 0.0001703
346 REGULATION OF PROTEIN MATURATION 5 82 1.322e-05 0.0001777
347 POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION 3 13 1.354e-05 0.0001811
348 REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY 3 13 1.354e-05 0.0001811
349 CELL CELL ADHESION 11 608 1.377e-05 0.0001836
350 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 4 40 1.426e-05 0.0001896
351 PLATELET ACTIVATION 6 142 1.435e-05 0.0001903
352 GLAND DEVELOPMENT 9 395 1.486e-05 0.0001964
353 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 15 1142 1.546e-05 0.0002038
354 RESPONSE TO ESTROGEN 7 218 1.608e-05 0.0002108
355 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 218 1.608e-05 0.0002108
356 RESPONSE TO IONIZING RADIATION 6 145 1.617e-05 0.0002113
357 INNATE IMMUNE RESPONSE 11 619 1.627e-05 0.000212
358 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 5 86 1.668e-05 0.0002167
359 RESPONSE TO ESTRADIOL 6 146 1.681e-05 0.0002173
360 CELLULAR RESPONSE TO INSULIN STIMULUS 6 146 1.681e-05 0.0002173
361 REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY 3 14 1.719e-05 0.0002215
362 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 6 147 1.747e-05 0.0002246
363 RESPONSE TO TRANSITION METAL NANOPARTICLE 6 148 1.816e-05 0.0002328
364 POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 5 88 1.865e-05 0.0002384
365 POSITIVE REGULATION OF CELL ACTIVATION 8 311 1.933e-05 0.0002464
366 EPITHELIAL CELL PROLIFERATION 5 89 1.97e-05 0.0002505
367 SINGLE ORGANISM CELLULAR LOCALIZATION 13 898 2.276e-05 0.0002886
368 REGULATION OF LEUKOCYTE DIFFERENTIATION 7 232 2.401e-05 0.0003036
369 NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS 6 156 2.446e-05 0.0003085
370 RESPONSE TO ANTIBIOTIC 4 47 2.73e-05 0.0003433
371 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 5 96 2.844e-05 0.0003567
372 NEGATIVE REGULATION OF PROTEOLYSIS 8 329 2.889e-05 0.0003614
373 ESTABLISHMENT OF LOCALIZATION IN CELL 18 1676 2.919e-05 0.0003641
374 REGULATION OF LIPID KINASE ACTIVITY 4 48 2.97e-05 0.0003695
375 INTERSPECIES INTERACTION BETWEEN ORGANISMS 11 662 3.019e-05 0.0003736
376 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 11 662 3.019e-05 0.0003736
377 NEGATIVE REGULATION OF CELL CYCLE 9 433 3.061e-05 0.0003778
378 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 13 926 3.136e-05 0.000386
379 NEGATIVE REGULATION OF ANOIKIS 3 17 3.185e-05 0.0003911
380 NEGATIVE REGULATION OF PEPTIDASE ACTIVITY 7 245 3.401e-05 0.0004165
381 POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 4 50 3.496e-05 0.0004269
382 POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY 3 18 3.812e-05 0.000462
383 REGULATION OF CELL CYCLE PROCESS 10 558 3.809e-05 0.000462
384 INOSITOL PHOSPHATE MEDIATED SIGNALING 3 18 3.812e-05 0.000462
385 CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM 7 252 4.069e-05 0.0004917
386 REGULATION OF LIPID CATABOLIC PROCESS 4 52 4.086e-05 0.0004926
387 ORGANOPHOSPHATE BIOSYNTHETIC PROCESS 9 450 4.13e-05 0.0004966
388 STRIATED MUSCLE CELL DIFFERENTIATION 6 173 4.372e-05 0.0005244
389 CELLULAR RESPONSE TO AMINO ACID STIMULUS 4 53 4.408e-05 0.0005272
390 NEGATIVE REGULATION OF MEIOTIC CELL CYCLE 3 19 4.515e-05 0.0005387
391 POSITIVE REGULATION OF CELL DIFFERENTIATION 12 823 4.561e-05 0.0005428
392 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 4 54 4.747e-05 0.000562
393 REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL 4 54 4.747e-05 0.000562
394 REGULATION OF CELL CYCLE ARREST 5 108 5.011e-05 0.0005903
395 REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 5 108 5.011e-05 0.0005903
396 POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 20 5.298e-05 0.0006209
397 REGULATION OF MACROPHAGE DIFFERENTIATION 3 20 5.298e-05 0.0006209
398 REGULATION OF MYELOID CELL DIFFERENTIATION 6 183 5.979e-05 0.0006972
399 REGULATION OF PROTEIN IMPORT 6 183 5.979e-05 0.0006972
400 B CELL HOMEOSTASIS 3 21 6.164e-05 0.0007117
401 NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS 3 21 6.164e-05 0.0007117
402 CELLULAR RESPONSE TO OXIDATIVE STRESS 6 184 6.163e-05 0.0007117
403 RESPONSE TO NITRIC OXIDE 3 21 6.164e-05 0.0007117
404 RESPONSE TO GROWTH FACTOR 9 475 6.269e-05 0.000722
405 GAMETE GENERATION 10 595 6.525e-05 0.0007496
406 REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS 3 22 7.119e-05 0.0008139
407 REGULATION OF PROTEIN HOMODIMERIZATION ACTIVITY 3 22 7.119e-05 0.0008139
408 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 10 602 7.191e-05 0.0008201
409 PROTEIN DEPHOSPHORYLATION 6 190 7.361e-05 0.0008374
410 POSITIVE REGULATION OF CELL ADHESION 8 376 7.402e-05 0.00084
411 REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 4 61 7.681e-05 0.0008696
412 GLUCOSE METABOLIC PROCESS 5 119 7.955e-05 0.0008984
413 REGULATION OF B CELL ACTIVATION 5 121 8.61e-05 0.00097
414 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 9 498 8.998e-05 0.001011
415 REGULATION OF ANOIKIS 3 24 9.307e-05 0.001041
416 T CELL DIFFERENTIATION 5 123 9.304e-05 0.001041
417 EMBRYO DEVELOPMENT 12 894 0.0001006 0.001123
418 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 5 126 0.0001043 0.001161
419 CELLULAR RESPONSE TO UV 4 66 0.0001046 0.001162
420 CELLULAR EXTRAVASATION 3 25 0.0001055 0.001169
421 REGULATION OF CELLULAR COMPONENT BIOGENESIS 11 767 0.0001133 0.001252
422 MULTICELLULAR ORGANISM REPRODUCTION 11 768 0.0001146 0.001264
423 CELLULAR COMPONENT DISASSEMBLY 9 515 0.000116 0.001276
424 DEVELOPMENTAL PROGRAMMED CELL DEATH 3 26 0.0001189 0.001302
425 NEGATIVE REGULATION OF LIPID TRANSPORT 3 26 0.0001189 0.001302
426 CELLULAR LIPID METABOLIC PROCESS 12 913 0.0001227 0.00134
427 GERM CELL DEVELOPMENT 6 209 0.0001243 0.001355
428 POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION 5 131 0.0001252 0.001362
429 POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION 4 70 0.0001316 0.001424
430 PROTEIN LOCALIZATION TO MITOCHONDRION 4 70 0.0001316 0.001424
431 REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 3 27 0.0001334 0.001437
432 DNA CATABOLIC PROCESS 3 27 0.0001334 0.001437
433 MACROMOLECULE CATABOLIC PROCESS 12 926 0.0001401 0.001502
434 REGULATION OF PROTEIN TARGETING 7 307 0.00014 0.001502
435 NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS 5 135 0.0001443 0.001543
436 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 28 0.000149 0.001583
437 RESPONSE TO COPPER ION 3 28 0.000149 0.001583
438 MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS 3 28 0.000149 0.001583
439 REGULATION OF HEMOPOIESIS 7 314 0.0001609 0.001705
440 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 4 74 0.0001633 0.001724
441 LIPID BIOSYNTHETIC PROCESS 9 539 0.0001634 0.001724
442 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 9 541 0.000168 0.001765
443 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 9 541 0.000168 0.001765
444 POSITIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS 4 75 0.000172 0.001803
445 NEGATIVE REGULATION OF B CELL ACTIVATION 3 30 0.0001837 0.001917
446 REGULATION OF ANION TRANSMEMBRANE TRANSPORT 3 30 0.0001837 0.001917
447 LYMPHOCYTE COSTIMULATION 4 78 0.0002002 0.002084
448 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 8 437 0.0002081 0.002161
449 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 4 79 0.0002103 0.00218
450 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 10 689 0.0002167 0.002241
451 NEGATIVE REGULATION OF LIPID METABOLIC PROCESS 4 80 0.0002208 0.002278
452 RESPONSE TO TEMPERATURE STIMULUS 5 148 0.0002216 0.002281
453 POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION 4 81 0.0002316 0.002379
454 REGULATION OF HOMEOSTATIC PROCESS 8 447 0.0002425 0.002486
455 MUSCLE CELL DIFFERENTIATION 6 237 0.0002458 0.002513
456 REPRODUCTION 14 1297 0.0002518 0.002569
457 PEPTIDYL AMINO ACID MODIFICATION 11 841 0.0002526 0.002571
458 REGULATION OF DNA METABOLIC PROCESS 7 340 0.0002615 0.002657
459 POSITIVE REGULATION OF CELL CYCLE ARREST 4 85 0.0002787 0.002826
460 NEGATIVE REGULATION OF PROTEIN PROCESSING 3 35 0.0002923 0.002944
461 HEXOSE METABOLIC PROCESS 5 157 0.0002912 0.002944
462 NEGATIVE REGULATION OF PROTEIN MATURATION 3 35 0.0002923 0.002944
463 REGULATION OF JNK CASCADE 5 159 0.0003087 0.003103
464 T CELL PROLIFERATION 3 36 0.000318 0.003179
465 LEUKOCYTE PROLIFERATION 4 88 0.0003183 0.003179
466 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 7 351 0.0003171 0.003179
467 NEGATIVE REGULATION OF KINASE ACTIVITY 6 250 0.0003271 0.003259
468 REGULATION OF MITOTIC CELL CYCLE 8 468 0.0003301 0.003282
469 RESPONSE TO HEAT 4 89 0.0003324 0.003284
470 B CELL DIFFERENTIATION 4 89 0.0003324 0.003284
471 REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY 4 89 0.0003324 0.003284
472 SEXUAL REPRODUCTION 10 730 0.0003435 0.003387
473 MODULATION BY VIRUS OF HOST MORPHOLOGY OR PHYSIOLOGY 3 37 0.0003451 0.003395
474 POSITIVE REGULATION OF HEMOPOIESIS 5 163 0.0003461 0.003398
475 CALCIUM MEDIATED SIGNALING 4 90 0.0003469 0.003398
476 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 0.0003618 0.003537
477 ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE 7 361 0.0003755 0.003663
478 BIOLOGICAL ADHESION 12 1032 0.0003795 0.003694
479 TISSUE DEVELOPMENT 15 1518 0.0003806 0.003697
480 ORGANOPHOSPHATE METABOLIC PROCESS 11 885 0.0003901 0.003781
481 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 3 39 0.0004038 0.00389
482 ERBB2 SIGNALING PATHWAY 3 39 0.0004038 0.00389
483 SPLEEN DEVELOPMENT 3 39 0.0004038 0.00389
484 REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS 4 94 0.0004094 0.003936
485 NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY 5 170 0.0004197 0.004027
486 FC GAMMA RECEPTOR SIGNALING PATHWAY 4 95 0.0004262 0.004081
487 REGULATION OF MEIOTIC CELL CYCLE 3 40 0.0004354 0.004149
488 REGULATION OF ACTIVATED T CELL PROLIFERATION 3 40 0.0004354 0.004149
489 ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE 6 264 0.000437 0.004149
490 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 9 616 0.0004368 0.004149
491 MYELOID LEUKOCYTE DIFFERENTIATION 4 96 0.0004435 0.004203
492 MITOTIC SPINDLE ASSEMBLY 3 41 0.0004685 0.004422
493 MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS 3 41 0.0004685 0.004422
494 CELLULAR RESPONSE TO ACID CHEMICAL 5 175 0.0004791 0.004499
495 PROTEIN LOCALIZATION TO MEMBRANE 7 376 0.0004789 0.004499
496 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 4 98 0.0004796 0.004499
497 MITOTIC CELL CYCLE 10 766 0.0005014 0.004694
498 REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 4 101 0.0005376 0.005021
499 MYELOID LEUKOCYTE MEDIATED IMMUNITY 3 43 0.0005395 0.005021
500 REGULATION OF POLYSACCHARIDE METABOLIC PROCESS 3 43 0.0005395 0.005021
501 NEGATIVE REGULATION OF ORGANELLE ORGANIZATION 7 387 0.0005684 0.005279
502 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 4 104 0.0006004 0.005565
503 POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION 3 45 0.0006171 0.005675
504 THYMOCYTE AGGREGATION 3 45 0.0006171 0.005675
505 MODIFICATION BY SYMBIONT OF HOST MORPHOLOGY OR PHYSIOLOGY 3 45 0.0006171 0.005675
506 T CELL DIFFERENTIATION IN THYMUS 3 45 0.0006171 0.005675
507 CARDIOVASCULAR SYSTEM DEVELOPMENT 10 788 0.0006247 0.005722
508 CIRCULATORY SYSTEM DEVELOPMENT 10 788 0.0006247 0.005722
509 PEPTIDYL THREONINE MODIFICATION 3 46 0.0006584 0.006019
510 DEPHOSPHORYLATION 6 286 0.0006656 0.006073
511 EPITHELIUM DEVELOPMENT 11 945 0.0006752 0.006148
512 REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS 2 11 0.0007269 0.006593
513 POSITIVE REGULATION OF HAIR CYCLE 2 11 0.0007269 0.006593
514 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS 3 48 0.0007462 0.006742
515 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE 3 48 0.0007462 0.006742
516 REGULATION OF TYPE I INTERFERON PRODUCTION 4 111 0.0007669 0.006915
517 REPRODUCTIVE SYSTEM DEVELOPMENT 7 408 0.000776 0.006984
518 REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY 3 49 0.0007928 0.007121
519 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 5 197 0.0008187 0.007322
520 OVULATION CYCLE 4 113 0.0008199 0.007322
521 POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY 5 197 0.0008187 0.007322
522 REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY 4 114 0.0008474 0.007553
523 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 5 199 0.0008566 0.007621
524 REGULATION OF VITAMIN METABOLIC PROCESS 2 12 0.0008702 0.007669
525 I KAPPAB PHOSPHORYLATION 2 12 0.0008702 0.007669
526 REPLICATIVE SENESCENCE 2 12 0.0008702 0.007669
527 MYELIN MAINTENANCE 2 12 0.0008702 0.007669
528 POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS 2 12 0.0008702 0.007669
529 REGULATION OF INTERLEUKIN 12 PRODUCTION 3 51 0.0008913 0.00784
530 FEMALE SEX DIFFERENTIATION 4 116 0.0009042 0.007938
531 MONOSACCHARIDE METABOLIC PROCESS 5 202 0.000916 0.008027
532 POSITIVE REGULATION OF LOCOMOTION 7 420 0.0009191 0.008039
533 PLASMA MEMBRANE ORGANIZATION 5 203 0.0009365 0.008175
534 CELLULAR RESPONSE TO IONIZING RADIATION 3 52 0.0009434 0.008202
535 REGULATION OF T CELL MEDIATED IMMUNITY 3 52 0.0009434 0.008202
536 NEGATIVE REGULATION OF PHOSPHORYLATION 7 422 0.0009449 0.008202
537 CELL MOTILITY 10 835 0.0009738 0.008407
538 LOCALIZATION OF CELL 10 835 0.0009738 0.008407
539 REGULATION OF IMMUNE EFFECTOR PROCESS 7 424 0.0009712 0.008407
540 REGULATION OF CELL DEVELOPMENT 10 836 0.0009827 0.008468
541 REGULATION OF LEUKOCYTE PROLIFERATION 5 206 0.0009999 0.008536
542 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 0.0009977 0.008536
543 REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS 3 53 0.0009974 0.008536
544 NEGATIVE REGULATION OF AUTOPHAGY 3 53 0.0009974 0.008536
545 REGULATION OF TRANSMEMBRANE TRANSPORT 7 426 0.0009981 0.008536
546 REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS 2 13 0.001026 0.00868
547 REGULATION OF MEMBRANE LIPID METABOLIC PROCESS 2 13 0.001026 0.00868
548 POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE 2 13 0.001026 0.00868
549 REGULATION OF PROTEIN POLYUBIQUITINATION 2 13 0.001026 0.00868
550 PROTEIN AUTOPROCESSING 2 13 0.001026 0.00868
551 NEGATIVE REGULATION OF REPRODUCTIVE PROCESS 3 54 0.001053 0.008862
552 LIPID METABOLIC PROCESS 12 1158 0.001051 0.008862
553 B CELL RECEPTOR SIGNALING PATHWAY 3 54 0.001053 0.008862
554 REGULATION OF B CELL PROLIFERATION 3 55 0.001111 0.009332
555 REGULATION OF ADAPTIVE IMMUNE RESPONSE 4 123 0.001124 0.009427
556 REGULATION OF FIBROBLAST APOPTOTIC PROCESS 2 14 0.001194 0.009904
557 NEGATIVE REGULATION OF CELL CYCLE PROCESS 5 214 0.001185 0.009904
558 INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 14 0.001194 0.009904
559 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 2 14 0.001194 0.009904
560 T CELL MIGRATION 2 14 0.001194 0.009904
561 DETERMINATION OF ADULT LIFESPAN 2 14 0.001194 0.009904
NumGOOverlapSizeP ValueAdj. P Value
1 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING 13 47 1.02e-21 9.477e-19
2 DEATH RECEPTOR BINDING 9 18 3.716e-18 1.726e-15
3 CYTOKINE RECEPTOR BINDING 17 271 1.216e-16 3.767e-14
4 KINASE ACTIVITY 24 842 1.654e-15 3.735e-13
5 ENZYME BINDING 32 1737 2.01e-15 3.735e-13
6 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS 7 15 4.459e-14 6.903e-12
7 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 24 992 6.11e-14 8.108e-12
8 PROTEIN SERINE THREONINE KINASE ACTIVITY 17 445 4.249e-13 4.934e-11
9 UBIQUITIN LIKE PROTEIN LIGASE BINDING 14 264 7.775e-13 8.026e-11
10 PROTEIN HETERODIMERIZATION ACTIVITY 17 468 9.542e-13 8.864e-11
11 X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 8 43 3.11e-12 2.627e-10
12 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 9 70 4.268e-12 3.304e-10
13 PROTEIN KINASE ACTIVITY 18 640 1.335e-11 8.359e-10
14 PHOSPHATIDYLINOSITOL KINASE ACTIVITY 8 51 1.334e-11 8.359e-10
15 TUMOR NECROSIS FACTOR RECEPTOR BINDING 7 30 1.35e-11 8.359e-10
16 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 9 86 2.879e-11 1.672e-09
17 KINASE BINDING 17 606 5.648e-11 3.086e-09
18 PROTEASE BINDING 9 104 1.632e-10 8.422e-09
19 DEATH RECEPTOR ACTIVITY 6 24 2.663e-10 1.302e-08
20 IDENTICAL PROTEIN BINDING 21 1209 1.501e-09 6.974e-08
21 ADENYL NUCLEOTIDE BINDING 23 1514 2.684e-09 1.187e-07
22 PROTEIN DIMERIZATION ACTIVITY 20 1149 3.925e-09 1.657e-07
23 RECEPTOR BINDING 22 1476 9.359e-09 3.78e-07
24 PROTEIN PHOSPHATASE BINDING 8 120 1.437e-08 5.562e-07
25 CYSTEINE TYPE PEPTIDASE ACTIVITY 9 184 2.564e-08 9.53e-07
26 KINASE REGULATOR ACTIVITY 9 186 2.816e-08 1.006e-06
27 ENZYME REGULATOR ACTIVITY 17 959 5.64e-08 1.928e-06
28 PROTEIN DOMAIN SPECIFIC BINDING 14 624 5.812e-08 1.928e-06
29 RIBONUCLEOTIDE BINDING 23 1860 1.265e-07 4.052e-06
30 PHOSPHATASE BINDING 8 162 1.492e-07 4.62e-06
31 MOLECULAR FUNCTION REGULATOR 19 1353 3.13e-07 9.086e-06
32 PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY 4 16 3.038e-07 9.086e-06
33 CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS 5 42 4.622e-07 1.301e-05
34 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 4 30 4.399e-06 0.0001202
35 PROTEIN COMPLEX BINDING 14 935 7.177e-06 0.0001905
36 INSULIN RECEPTOR SUBSTRATE BINDING 3 11 7.854e-06 0.0002027
37 SIGNAL TRANSDUCER ACTIVITY 19 1731 1.212e-05 0.0003043
38 PROTEIN KINASE A BINDING 4 42 1.737e-05 0.0004247
39 PROTEIN KINASE A CATALYTIC SUBUNIT BINDING 3 15 2.143e-05 0.0005104
40 INTERLEUKIN 1 RECEPTOR BINDING 3 16 2.63e-05 0.0006109
41 ENDOPEPTIDASE ACTIVITY 9 448 3.99e-05 0.0009041
42 MACROMOLECULAR COMPLEX BINDING 16 1399 4.213e-05 0.0009319
43 PROTEIN HOMODIMERIZATION ACTIVITY 11 722 6.619e-05 0.00143
44 ENZYME INHIBITOR ACTIVITY 8 378 7.68e-05 0.001622
45 CAMP BINDING 3 23 8.165e-05 0.001649
46 CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS 3 23 8.165e-05 0.001649
47 PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY 4 64 9.274e-05 0.001833
48 PEPTIDASE REGULATOR ACTIVITY 6 214 0.0001414 0.002737
49 PROTEIN PHOSPHATASE 2A BINDING 3 28 0.000149 0.002826
50 CYCLIC NUCLEOTIDE BINDING 3 36 0.000318 0.005908
51 KINASE INHIBITOR ACTIVITY 4 89 0.0003324 0.006055
52 PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 5 178 0.0005177 0.009248
NumGOOverlapSizeP ValueAdj. P Value
1 MEMBRANE MICRODOMAIN 19 288 5.919e-19 3.456e-16
2 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 17 237 1.267e-17 3.7e-15
3 CATALYTIC COMPLEX 27 1038 1.652e-16 3.216e-14
4 PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX 8 20 2.891e-15 4.22e-13
5 MEMBRANE PROTEIN COMPLEX 25 1020 1.17e-14 1.366e-12
6 TRANSFERASE COMPLEX 18 703 6.226e-11 6.06e-09
7 PROTEIN KINASE COMPLEX 8 90 1.448e-09 1.208e-07
8 MEMBRANE REGION 20 1134 3.135e-09 2.289e-07
9 PLASMA MEMBRANE PROTEIN COMPLEX 14 510 4.622e-09 2.999e-07
10 CILIARY BASE 5 23 1.931e-08 1.128e-06
11 CD40 RECEPTOR COMPLEX 4 11 5.587e-08 2.966e-06
12 CYTOSOLIC PART 9 223 1.336e-07 6.503e-06
13 MITOCHONDRION 21 1633 2.77e-07 1.244e-05
14 RECEPTOR COMPLEX 9 327 3.251e-06 0.0001356
15 EXTRINSIC COMPONENT OF MEMBRANE 8 252 4.181e-06 0.0001628
16 IKAPPAB KINASE COMPLEX 3 11 7.854e-06 0.0002867
17 PHOSPHATASE COMPLEX 4 48 2.97e-05 0.00102
18 PLASMA MEMBRANE RECEPTOR COMPLEX 6 175 4.662e-05 0.001513
19 OUTER MEMBRANE 6 190 7.361e-05 0.002263
20 INTRINSIC COMPONENT OF PLASMA MEMBRANE 17 1649 8.527e-05 0.00249
21 MITOCHONDRIAL ENVELOPE 10 691 0.0002218 0.006168
22 PLASMA MEMBRANE RAFT 4 86 0.0002915 0.007738

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04210_Apoptosis 74 89 7.651e-195 1.354e-192
2 hsa04380_Osteoclast_differentiation 25 128 3.237e-37 2.864e-35
3 hsa04620_Toll.like_receptor_signaling_pathway 23 102 8.817e-36 5.202e-34
4 hsa04722_Neurotrophin_signaling_pathway 24 127 2.514e-35 1.112e-33
5 hsa04660_T_cell_receptor_signaling_pathway 22 108 3.882e-33 1.374e-31
6 hsa04662_B_cell_receptor_signaling_pathway 20 75 9.615e-33 2.836e-31
7 hsa04650_Natural_killer_cell_mediated_cytotoxicity 22 136 9.521e-31 2.408e-29
8 hsa04010_MAPK_signaling_pathway 26 268 2.202e-30 4.871e-29
9 hsa04370_VEGF_signaling_pathway 17 76 2.044e-26 4.019e-25
10 hsa04910_Insulin_signaling_pathway 19 138 3.741e-25 6.622e-24
11 hsa04062_Chemokine_signaling_pathway 19 189 1.85e-22 2.978e-21
12 hsa04914_Progesterone.mediated_oocyte_maturation 14 87 1.074e-19 1.584e-18
13 hsa04510_Focal_adhesion 17 200 6.994e-19 9.523e-18
14 hsa04973_Carbohydrate_digestion_and_absorption 11 44 5.694e-18 7.199e-17
15 hsa04920_Adipocytokine_signaling_pathway 12 68 1.597e-17 1.884e-16
16 hsa04622_RIG.I.like_receptor_signaling_pathway 12 71 2.783e-17 3.079e-16
17 hsa04150_mTOR_signaling_pathway 11 52 4.382e-17 4.563e-16
18 hsa04664_Fc_epsilon_RI_signaling_pathway 12 79 1.088e-16 1.07e-15
19 hsa04012_ErbB_signaling_pathway 12 87 3.682e-16 3.43e-15
20 hsa04621_NOD.like_receptor_signaling_pathway 10 59 1.39e-14 1.23e-13
21 hsa04630_Jak.STAT_signaling_pathway 13 155 1.522e-14 1.282e-13
22 hsa04666_Fc_gamma_R.mediated_phagocytosis 11 95 5.001e-14 4.024e-13
23 hsa04115_p53_signaling_pathway 10 69 7.305e-14 5.621e-13
24 hsa04960_Aldosterone.regulated_sodium_reabsorption 8 42 2.539e-12 1.872e-11
25 hsa04070_Phosphatidylinositol_signaling_system 8 78 4.537e-10 3.212e-09
26 hsa04720_Long.term_potentiation 7 70 7.067e-09 4.811e-08
27 hsa04670_Leukocyte_transendothelial_migration 8 117 1.177e-08 7.713e-08
28 hsa04623_Cytosolic_DNA.sensing_pathway 6 56 5.852e-08 3.7e-07
29 hsa04310_Wnt_signaling_pathway 8 151 8.666e-08 5.289e-07
30 hsa04114_Oocyte_meiosis 7 114 2.132e-07 1.258e-06
31 hsa04810_Regulation_of_actin_cytoskeleton 8 214 1.239e-06 7.077e-06
32 hsa04020_Calcium_signaling_pathway 7 177 4.124e-06 2.281e-05
33 hsa00562_Inositol_phosphate_metabolism 4 57 5.88e-05 0.0003154
34 hsa04141_Protein_processing_in_endoplasmic_reticulum 5 168 0.0003976 0.00207
35 hsa04962_Vasopressin.regulated_water_reabsorption 3 44 0.0005775 0.00292
36 hsa04742_Taste_transduction 3 52 0.0009434 0.004638
37 hsa04340_Hedgehog_signaling_pathway 3 56 0.001171 0.005601
38 hsa04360_Axon_guidance 4 130 0.00138 0.006427
39 hsa04976_Bile_secretion 3 71 0.00232 0.01053
40 hsa04971_Gastric_acid_secretion 3 74 0.002611 0.01155
41 hsa04640_Hematopoietic_cell_lineage 3 88 0.00426 0.01839
42 hsa04970_Salivary_secretion 3 89 0.004397 0.01853
43 hsa04540_Gap_junction 3 90 0.004536 0.01867
44 hsa04912_GnRH_signaling_pathway 3 101 0.006251 0.02459
45 hsa04916_Melanogenesis 3 101 0.006251 0.02459
46 hsa04270_Vascular_smooth_muscle_contraction 3 116 0.00914 0.03517
47 hsa04530_Tight_junction 3 133 0.01322 0.04979
48 hsa04120_Ubiquitin_mediated_proteolysis 3 139 0.01487 0.05484
49 hsa04110_Cell_cycle 2 128 0.08151 0.2944
50 hsa04740_Olfactory_transduction 3 388 0.1735 0.6023

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

UCA1

hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-140-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-3065-5p;hsa-miR-339-5p;hsa-miR-455-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-628-3p;hsa-miR-7-1-3p 15 IL1RAP Sponge network 1.481 0.28957 0.24 0.6772 0.623
2

HCG11

hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-376a-3p;hsa-miR-376b-3p;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-7-1-3p 11 PIK3CA Sponge network -0.31 0.48859 -0.202 0.54123 0.543
3

RFPL1S

hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-33a-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-96-5p 17 BCL2 Sponge network -0.457 0.43621 -1.629 0.00261 0.539
4

HCG11

hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-29a-5p;hsa-miR-29b-3p;hsa-miR-3065-5p;hsa-miR-455-5p 14 BCL2 Sponge network -0.31 0.48859 -1.629 0.00261 0.503
5 CECR7 hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-429 11 BCL2 Sponge network -0.527 0.47624 -1.629 0.00261 0.495
6 MIR155HG hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-181c-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-3065-5p;hsa-miR-33b-5p;hsa-miR-375 10 PRKX Sponge network -1.955 0.00055 -0.87 0.01822 0.489
7

RFPL1S

hsa-miR-106b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-429;hsa-miR-96-5p 11 PIK3R1 Sponge network -0.457 0.43621 -0.508 0.16815 0.458
8 HCP5 hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-181c-5p;hsa-miR-330-3p;hsa-miR-33b-5p;hsa-miR-375;hsa-miR-409-3p;hsa-miR-495-3p;hsa-miR-539-5p;hsa-miR-96-5p 12 PRKX Sponge network -0.577 0.20814 -0.87 0.01822 0.446
9

HCG11

hsa-miR-106b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-29b-3p;hsa-miR-3065-5p;hsa-miR-590-3p 12 PIK3R1 Sponge network -0.31 0.48859 -0.508 0.16815 0.423
10

DIO3OS

hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-139-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-455-5p;hsa-miR-582-5p 14 IL1RAP Sponge network 1.18 0.0997 0.24 0.6772 0.366
11

HCG11

hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-200a-3p;hsa-miR-29b-2-5p;hsa-miR-340-5p;hsa-miR-369-3p;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-7-1-3p 11 IRAK3 Sponge network -0.31 0.48859 -0.545 0.29063 0.336
12 PVT1 hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-139-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-301a-3p;hsa-miR-361-5p;hsa-miR-455-5p;hsa-miR-543;hsa-miR-582-5p 10 IL1RAP Sponge network 0.67 0.32654 0.24 0.6772 0.334
13 EGOT hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-3200-3p;hsa-miR-324-5p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-369-3p;hsa-miR-421;hsa-miR-7-1-3p 11 IRAK3 Sponge network -1.196 0.1622 -0.545 0.29063 0.332
14

DIO3OS

hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-324-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-501-5p;hsa-miR-582-5p;hsa-miR-589-3p 10 IRAK3 Sponge network 1.18 0.0997 -0.545 0.29063 0.33
15 H19 hsa-miR-103a-2-5p;hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-181c-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-29b-3p;hsa-miR-495-3p;hsa-miR-539-5p 12 PRKX Sponge network -0.02 0.98077 -0.87 0.01822 0.325
16

UCA1

hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-501-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-628-3p;hsa-miR-7-1-3p 13 IRAK3 Sponge network 1.481 0.28957 -0.545 0.29063 0.31
17

HCG11

hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-19b-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-3065-5p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-362-3p;hsa-miR-455-5p;hsa-miR-590-3p;hsa-miR-664a-3p;hsa-miR-7-1-3p 15 IL1RAP Sponge network -0.31 0.48859 0.24 0.6772 0.307
18 FAM66C hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-34a-5p 10 BCL2 Sponge network -0.537 0.25424 -1.629 0.00261 0.251

Quest ID: 46d53ea419e09bc3eb6eb4928a6093b4